EGFR and non-small cell lung carcinoma: Furthermore, the aforementioned amivantamab (JNJ-61186372) is also a fourth generation EGFR TKI, which has shown preclinical activity in TKI-sensitive EGFR-mutated NSCLC models and in the ongoing CHRYSALIS study (68).